Robert Cabrera/LinkedIn
Sep 24, 2025, 15:57
Robert Cabrera & Colleagues Developed the ELISA-Based Folate Receptor Autoantibody Assay
Robert Cabrera, Associate Professor at Baylor College of Medicine, shared on LinkedIn:
“I (we) developed the ELISA-based folate receptor autoantibody assay in 2008 based on Rothenberg’s 2004 study on neurodevelopmental risks (NTDs).
Today, 17-21 years later, folate receptor autoantibodies were mentioned in a US Presidential press conference on autism, which included Tylenol (acetaminophen) risks, and proposed treatment with reduced folate (folinic acid, leucovorin).”
Title: Autoantibodies to folate receptor during pregnancy and neural tube defect risk
Authors: Robert M Cabrera, Gary M Shaw, Johnathan L Ballard, Suzan L Carmichael, Wei Yang, Edward J Lammer, Richard H Finnell
Read more here.
Stay updated with Hemostasis Today.
acetaminophen
Autoantibody
Baylor College of Medicine
Edward J Lammer
ELISA
folinic acid
Gary M Shaw
Health
Hematology
Hemostasis
Hemostasis Today
Johnathan L Ballard
leucovorin
Medicine
neural tube defect
Neurodevelopmental Risks
Pregnancy
Richard H Finnell
Robert M Cabrera
Suzan L Carmichael
thrombosis
Tylenol
Wei Yang
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals
Sep 29, 2025, 12:54
Sep 29, 2025, 12:33
Sep 29, 2025, 06:23
Sep 29, 2025, 05:06
Sep 29, 2025, 04:28